Glenmark Pharmaceuticals Receives ANDA Approval for Clindamycin and Benzoyl Peroxide Gel

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin and Benzoyl Peroxide Gel, 1 percent|5 percent, a generic version of BenzaClin Gel, 1 percent|5 percent, of Valeant Bermuda. According to IQVIATM sales data for the 12-month period ending January 2019, the BenzaClin Gel, 1 percent|5 percent market achieved annual sales of approximately USD 99.4 million*. Glenmark’s current portfolio consists of 151 products authorized for distribution in the U.S. marketplace and 53 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. – Medical Buyer Bureau